Adjuvant Pembrolizumab in Renal-Cell Carcinoma

被引：1

作者：

Chakiryan, Nicholas H. ^{[1
]}

Strother, Marshall C. ^{[1
]}

Choueiri, Toni K. ^{[2
]}

Powles, Thomas ^{[3
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97239 USA

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Barts Canc Inst, London, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 391卷 / 02期

关键词：

D O I：

10.1056/NEJMc2406031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: Choueiri et al. (April 18 issue)(1) report the much-anticipated overall survival results from KEYNOTE-564, a successful trial of adjuvant therapy for patients with high-risk clear-cell renal-cell carcinoma. Receipt of adjuvant pembrolizumab after nephrectomy was associated with a significant overall survival benefit over placebo: 91.2% as compared with 86.0% at 48 months (hazard ratio for death, 0.62; 95% confidence interval, 0.44 to 0.87; P=0.005). Despite statistical significance and an impressive hazard ratio, the effect size was modest. The absolute survival difference of 5.2 percentage points at 48 months implies a number needed to treat of 19.2, as compared . . .

引用

页码：185 / 186

页数：2

共 1 条

[1] Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Symeonides, S. N. ;

Hajek, J. ;

Chang, Y-H ;

Lee, J-L ;

Sarwar, N. ;

Haas, N. B. ;

Gurney, H. ;

Sawrycki, P. ;

Mahave, M. ;

Gross-Goupil, M. ;

Zhang, T. ;

Burke, J. M. ;

Doshi, G. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Oudard, S. ;

Topart, D. ;

Hammers, H. ;

Kitamura, H. ;

McDermott, D. F. ;

Silva, A. ;

Winquist, E. ;

Cornell, J. ;

Elfiky, A. ;

Burgents, J. E. ;

Perini, R. F. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (15) :1359-1371

← 1 →